Adam Silverstein
Overview
Explore the profile of Adam Silverstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knopman D, Laskowitz D, Koltai D, Charvet L, Becker J, Federman A, et al.
Trials
. 2024 May;
25(1):326.
PMID: 38755688
Background: Post-acute sequelae of SARS-CoV-2 infection (PASC) symptoms have broad impact, and may affect individuals regardless of COVID-19 severity, socioeconomic status, race, ethnicity, or age. A prominent PASC symptom is...
2.
OHalloran J, Ko E, Anstrom K, Kedar E, McCarthy M, Panettieri Jr R, et al.
JAMA
. 2023 Jul;
330(4):328-339.
PMID: 37428480
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19. Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, And...
3.
Ko E, Anstrom K, Panettieri R, Lachiewicz A, Maillo M, OHalloran J, et al.
medRxiv
. 2022 Oct;
PMID: 36203544
Background: We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods: We conducted a master protocol to investigate immunomodulators...
4.
Kolb M, Orfanos S, Lambers C, Flaherty K, Masters A, Lancaster L, et al.
Adv Ther
. 2022 Jul;
39(9):3881-3895.
PMID: 35781186
Interstitial lung diseases (ILD) encompasses a heterogeneous group of parenchymal lung diseases characterized by variable amounts of inflammation and fibrosis. The targeting of fibroblasts and myofibroblasts with antifibrotic treatments is...
5.
Lang J, Hornik C, Elliott C, Silverstein A, Hornik C, Al-Uzri A, et al.
Pediatr Infect Dis J
. 2022 Jun;
41(7):556-562.
PMID: 35675525
Background: Solithromycin is a new macrolide-ketolide antibiotic with potential effectiveness in pediatric community-acquired bacterial pneumonia (CABP). Our objective was to evaluate its safety and effectiveness in children with CABP. Methods:...
6.
Held C, White H, Stewart R, Davies R, Sampson S, Chiswell K, et al.
Am Heart J
. 2018 Dec;
208:65-73.
PMID: 30572273
Background: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828...
7.
Benyahia C, Ozen G, Orie N, Ledwozyw A, Louedec L, Li F, et al.
Prostaglandins Other Lipid Mediat
. 2015 Sep;
121(Pt A):46-52.
PMID: 26362969
Prostacyclin (PGI2) mimetics (iloprost, treprostinil) are potent vasodilators (primarily via IP-receptor activation) and major therapeutic interventions for pulmonary hypertension (PH). Increased plasma levels of endothelin (ET-1), thromboxane (TxA2) and catecholamines...
8.
Benyahia C, Boukais K, Gomez I, Silverstein A, Clapp L, Fabre A, et al.
Prostaglandins Other Lipid Mediat
. 2013 Jul;
107:48-55.
PMID: 23850788
Prostacyclin (PGI2) and its mimetics (iloprost, treprostinil, beraprost and MRE-269) are potent vasodilators (via IP-receptor activation) and a major therapeutic intervention for pulmonary hypertension (PH). These PGI2 mimetics have anti-proliferative...